Treating poor nasal breathers simply and non-surgically
This article was originally published in Start Up
Faced with the large unmet clinical need of people with chronic nasal obstruction, an ENT physician formed Spirox to develop a non-surgical implant to restore the nasal valve. The ultimate goal is to develop a 15-minute procedure that ENTs can perform in their office to help patients breathe better.
You may also be interested in...
Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.
The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.
The Irish firm revealed it was in early conversations with Amgen, J&J and Sanofi regarding a possible takeover, with some experts touting the potential for a deal far surpassing the $20bn mark.